Indolent Systemic Mastocytosis
📧 Sign up to get email alerts when something new happens for Indolent Systemic Mastocytosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
An observational study in participants with Indolent Systemic Mastocytosis (ISM) is currently in recruitment. The sponsor is Blueprint Medic…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis [Phase 2, Phase 3]
A clinical trial update describing the ongoing HARBOR study evaluating BLU-263 versus placebo in patients with indolent systemic mastocytosi…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
A non-interventional study in Germany is currently recruiting participants with indolent systemic mastocytosis to collect observational data…
-
CLINICAL_TRIALS trial_result · 2026-03-09Clinical Trial Update: Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
The document reports expanded access for Bezuclastinib to patients with nonadvanced or advanced systemic mastocytosis.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis [Phase 2]
Phase 2 clinical trial update evaluating CGT9486 vs placebo in indolent or smoldering systemic mastocytosis. The study is currently active b…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis [Phase 2]
The document outlines a Phase 2 clinical trial, PIONEER, evaluating the efficacy and safety of avapritinib versus placebo in patients with i…
-
CLINICAL_TRIALS trial_result · 2024-12-17Clinical Trial Update: Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis [Phase 2]
This Phase 2 trial evaluated subcutaneous sarilumab for improving quality of life in people with indolent systemic mastocytosis; results hav…
-
CLINICAL_TRIALS research · 2024-05-10Clinical Trial Update: Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis [Phase 2]
Phase 2 study of TL-895 in patients with myelofibrosis or indolent systemic mastocytosis is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2023-05-06Clinical Trial Update: Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment [Phase 3]
A Phase 3 trial of masitinib in severe Indolent Systemic Mastocytosis unresponsive to optimal symptomatic treatment is underway, with status…
-
CLINICAL_TRIALS trial_result · 2019-12-03Clinical Trial Update: Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis [Phase 3]
Phase 3 clinical trial update for masitinib in indolent systemic mastocytosis has completed.
-
CLINICAL_TRIALS trial_result · 2017-01-10Clinical Trial Update: Patient-Reported Outcome Questionnaire for Systemic Mastocytosis
A clinical trial update on a patient-reported outcome questionnaire for systemic mastocytosis, with the study status marked as completed.
-
CLINICAL_TRIALS trial_result · 2016-09-29Clinical Trial Update: Treatment of Indolent Systemic Mastocytosis With PA101 [Phase 2]
A Phase 2 clinical trial evaluating PA101 for indolent systemic mastocytosis has completed.
-
CLINICAL_TRIALS trial_result · 2015-01-19Clinical Trial Update: Midostaurin in Indolent Systemic Mastocytosis [Phase 2]
A Phase 2 clinical trial update for midostaurin in indolent systemic mastocytosis; current status is unknown.